"Gilead Invests $100M in Assembly Bio for Breakthrough Antiviral Therapies"
Gilead has partnered with Assembly Bio to develop new antiviral treatments for herpesviruses, hepatitis B, and hepatitis D. Gilead will provide $100 million in funding, including cash and equity investment, and has the potential to offer up to $1.9 billion in milestone payments for successful clinical programs.